Molecular and Cellular Biology, October 2000, p. 7624-7633, Vol. 20, No. 20
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115
Received 11 May 2000/Returned for modification 8 June 2000/Accepted 26 July 2000
| |
ABSTRACT |
|---|
|
|
|---|
At least three domains of simian virus 40 large T antigen (TAg)
participate in cellular transformation. The LXCXE motif of TAg binds to
all members of the retinoblastoma protein (pRB) family of tumor
suppressors. The N-terminal 70 residues of TAg have significant homology to the J domain of Hsp40/DnaJ and cooperate with the LXCXE
motif to inactivate the pRB family. A bipartite C-terminal domain of
TAg binds to p53 and thereby disrupts the ability of p53 to act as a
sequence-specific transcription factor. The contribution of these three
domains of TAg to cellular transformation was evaluated in cells that
contained inactivating mutations in the pRB and p53 pathways. Cells
that stably expressed wild-type or selected mutant forms of TAg were
generated in mouse embryo fibroblasts (MEFs) containing homozygous
deletions in the RB, INK4a, and ARF loci. It was determined that the J domain, the LXCXE motif, and the
p53-binding domain of TAg were required for full transformation of
wild-type and RB
/
MEFs. In contrast,
INK4a
/
MEFs that lacked expression of
p16INK4a and p19ARF and
ARF
/
MEFs that lacked
p19ARF but expressed
p16INK4a acquired anchorage-independent growth
when expressing wild-type TAg or mutant derivatives that disrupted
either the pRB-binding or p53-binding domain. The expression and
function of the pRB family members were not overly disrupted in
ARF
/
MEFs expressing LXCXE mutants of TAg.
These results suggest that inactivating mutations of
p19ARF can relieve the requirement for the
LXCXE motif in TAg-mediated transformation and that TAg may have
additional functions in transformation.
| |
INTRODUCTION |
|---|
|
|
|---|
Simian virus 40 (SV40) large T antigen (TAg) has been used extensively as a model system to study cellular transformation. TAg has the ability to transform a wide variety of normal cells seemingly by affecting the functions of a small number of cellular proteins. To transform wild-type (WT) mouse embryo fibroblasts (MEFs), TAg utilizes at least three domains: the J domain, the LXCXE motif that binds to the retinoblastoma protein (pRB) family of proteins (pRB, p107, and p130), and the p53-binding domain (12, 13, 17, 20, 65, 77, 81). The J domain is a highly conserved element present in all members of the DnaJ/Hsp40 family of molecular chaperones as well as all polyomavirus T antigens (39). DnaJ proteins bind specifically to hsp70 homologues to perform various chaperone activities, including the destruction of specific proteins (reviewed in reference 63). The J domain of TAg binds to hsc70 and participates in the inactivation of pRB family members (27, 56, 60, 68, 69). The J domain and the LXCXE motif of TAg cooperate to disrupt the ability of pRB family members to repress E2F-dependent transcription and to decrease the levels of hyperphosphorylated p107 and p130 (27, 60, 64, 65, 68, 69, 77). Thus, the J domain and LXCXE motif of TAg appear to induce transformation and promote cell growth by interfering with the functions of pRB, p107, and p130. The p53-binding domain of TAg binds to the specific DNA-binding domain of p53, thereby directly interfering with the ability of p53 to activate transcription (3, 21, 51). Therefore, it is believed that TAg can transform cells primarily by interfering with p53 and the pRB family.
The original observations that TAg binds to p53 and the pRB family set
into motion a large field of research that has led to a more complete
understanding of the role of these tumor suppressors in the development
of cancer (13, 44, 46). Not only is pRB itself mutated in a
wide variety of cancers, wild-type pRB can be functionally
inactivated by expression of an LXCXE-containing viral
oncoprotein. pRB can also be inactivated by hyperphosphorylation as a
result of overexpression of cyclin D1 or loss of expression p16INK4a. p16INK4a binds
to cdk4 and blocks the association of cdk4 with D-type cyclins
(57). Overexpression of p16INK4a in
RB+/+ cells prevents phosphorylation and
subsequent inactivation of pRB by cyclin D1-cdk4 and promotes a cell
cycle arrest in G1 (41, 48). In contrast,
p16INK4a is unable to induce a cell cycle arrest
in RB
/
cells, suggesting that the pRB
pathway is required for p16INK4a-mediated cell
cycle arrest (48). p16INK4a may also
affect the phosphorylation status of p107 and p130, as each of these
proteins migrates as a lower-phosphorylation form in sodium dodecyl
sulfate (SDS)-polyacrylamide gel electrophoresis after
p16INK4a overexpression (74;
J. Zalvide and J. A. DeCaprio, unpublished observations).
Therefore, p16INK4a may regulate all three
members of the pRB family.
In addition to p16INK4a, the INK4a locus encodes a second gene product, p19ARF (54). While each of these proteins is encoded by a unique first exon, the second and third exons encode p19ARF in an alternate reading frame than p16INK4a (54). It has been demonstrated that p19ARF binds and inactivates MDM2 (36, 52, 67, 80). Since MDM2 contributes to the degradation of p53, overexpression of p19ARF can result in an increased amount of p53, leading to an arrest in G1 (28, 80). Therefore, through the expression of p16INK4a and p19ARF, the INK4a locus apparently participates in the regulation of both the pRB and p53 pathways.
Although TAg-mediated transformation is thought to involve primarily
the inactivation of pRB family members and p53, studies of mice that
contain mutations in the INK4a locus would seem to indicate
that the functional inactivation of pRB and p53 is not sufficient to
cause cellular transformation. INK4a knockout mice lack the
second and third exons of the INK4a locus and do not express
p16INK4a or p19ARF,
although they may express a truncated version of
p19ARF that may be partially active (5, 53,
58). Despite this interference with both the p53 and pRB
pathways, INK4a
/
MEFs were not transformed.
Although they readily became immortalized, INK4a
/
MEFs were unable to grow in
soft agar and required the expression of activated H-ras to
become transformed (37, 58).
INK4a
/
mice do have an increased incidence
of several types of tumors including lymphomas and fibrosarcomas, which
presumably occur after the mice receive additional genetic mutations
(58). Curiously, the ARF
/
mice
that fail to express p19ARF but retain
expression of WT p16INK4a display a similar
range of tumors as the INK4a
/
mice that have
lost both p19ARF and
p16INK4a (35, 37). In addition, the
ARF
/
MEFs were readily immortalized and
could be transformed by activated H-ras alone similarly to
the INK4a
/
MEFs (37). Therefore,
at least in the mouse model, it has been difficult to observe the
specific contribution of p16INK4a to tumor
suppression since the INK4a
/
and
ARF
/
knockouts result in a similar phenotype.
Given that disruption of the INK4a locus was not sufficient
to induce transformation of MEFs, the pRB and p53 pathways may retain
some of their tumor suppressor activity in
INK4a
/
cells. Indeed, it has been noted that
p53 can be activated in the ARF
/
MEFs by
ionizing radiation but not by adenovirus E1A (14, 37). It is
thus possible that p53 may retain the ability to act as a tumor
suppressor under some conditions in the ARF
/
and INK4a
/
mice. Alternatively, there may be
tumor suppressor pathways other than pRB and p53 that retain activity
in the INK4a
/
or
ARF
/
MEFs. We wished to determine whether
the loss or functional inactivation of tumor suppressor genes that are
targeted by TAg would abrogate the need for the J domain, the LXCXE
motif, or the p53-binding domain in TAg-mediated transformation. Using
this approach, it had been previously demonstrated that the LXCXE motif
was required to transform RB
/
MEFs,
suggesting that p107 and p130 were also targeted by the LXCXE motif
(11, 76). To identify additional pathways that may be
targeted by SV40 TAg, we generated WT, RB
/
,
ARF
/
, and INK4a
/
MEFs that stably expressed WT or selected mutants of TAg. We observed
that TAg could fully transform MEFs from each of these genetic
backgrounds. Notably, the LXCXE motif was absolutely required for
transformation of WT and RB
/
MEFs but was
dispensable for anchorage-independent growth of ARF
/
and INK4a
/
MEFs, suggesting that the pRB pathway was functionally inactivated by
loss of p19ARF. However, pRB family members were
expressed normally, and their ability to repress E2F activity was
intact in the ARF
/
and
INK4a
/
MEFs expressing the LXCXE mutants of
TAg. These results suggest the possibility that TAg's LXCXE motif may
functionally inactivate other growth suppressors in addition to the pRB
family and that p19ARF may have activity beyond
the regulation of MDM2 and p53.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Plasmids. The SV40 large TAg cDNA expression plasmids pSG5-T, pSG5-H42Q, pSG5-K1, pSG5-C105G, and pSG5-PVU-1 have been previously described (69, 76). pSG5-dl434-444 was cloned by substituting the PflMI-PstI fragment from dl434-444 containing the mutant p53-binding site into pSG5-T (40). pSG5-HQ-K1 was similarly cloned by substituting the PflMI-PstI fragment of pSG5-K1 into pSG5-HQ. pSG5-T1-135 and pSG5-T1-350 were generated by PCR amplification of a TAg cDNA with the appropriate primers. DNA sequencing confirmed the identity of all constructs.
The p21 promoter-luciferase reporter, pWWP-luc, has been previously described (19), as has the 3xE2F-luciferase reporter, 3xE2F-Luc, containing three specific E2F DNA-binding sites (50). The cyclin G-luciferase reporter, pGL3-cyclin G-Luc, was obtained from Carol Prives. The
-galactosidase reporter plasmid,
pCMX-
-Gal, was used as a control for transfection efficiency
(23).
Cells.
INK4a
/
MEFs and
ARF
/
MEFs have been previously described
(37, 58). RB
/
and WT MEFs were
prepared from 13.5-day embryos as previously described (32,
76). All MEFs were cultured in Dulbecco modified Eagle medium
(DMEM) containing 10% Fetal Clone Serum I (HyClone) and
penicillin-streptomycin. MEFs were cotransfected with pEpuro and
fivefold excess SV40 TAg-encoding plasmid by the calcium phosphate precipitation method or Fugene 6 (Boehringer Mannheim). After 16 h
of exposure to the plasmid DNA, cells were refed with complete medium
and grown for 24 h before splitting into medium containing puromycin (2 µg/ml). Before reaching confluence, colonies were pooled
and expanded in three 100-mm-diameter plates, at which point they were
considered to be established. Cells of no more than three passages
after this stage were used for transformation studies and were always
passaged at subconfluence.
Western blotting and antibodies. Cells were lysed in high-salt EBC (50 mM Tris-HCl [pH 8.0], 300 mM NaCl, 0.5% Nonidet P-40) containing aprotinin (10 µg/ml), leupeptin (10 µg/ml), 0.1 mM phenylmethylsulfonyl fluoride, 4 mM sodium fluoride, and 0.1 mM sodium orthovanadate. Lysates were cleared by centrifugation at 14,000 × g, and protein concentration was determined by the Bradford assay (Bio-Rad); 100 µg of each sample was separated in SDS-polyacrylamide gels and transferred to nitrocellulose membranes (Bio-Rad). The membranes were blocked for 1 h with 5% nonfat dry milk and 1% goat serum in TBS-T (10 mM Tris-HCl [pH 8.0], 150 mM NaCl, 0.1% Tween 20), before overnight incubation with the primary antibody in TBS-T containing 1% bovine serum albumin at 4°C. The following antibodies were used in this study: anti-TAg polyclonal antibodies (PAb) 101 and 419 (26) (American Type Culture Collection), anti-RB PAb 245 (Pharmingen), anti-p107 C-18 (Santa Cruz Biotechnology), anti-p130 C-20 (Santa Cruz), anti-p53 FL-393 (Santa Cruz), anti-p15INK4b Ab-3 (Neomarkers), anti-p16INK4a M-156 (Santa Cruz), and anti-p21CIP1 C-19 (Santa Cruz). The anti-p19ARF rabbit PAb was previously described (37). Detection of proteins was performed with the appropriate horseradish peroxidase-conjugated secondary rabbit or goat antibody (Pierce) at a 1:5,000 dilution in TBS-T containing 2.5% milk and 0.5% goat serum. Immunoblots were developed using enhanced chemiluminescence (Pierce) according to the manufacturer's protocol.
Transformation assays. Soft agar assays were performed in 35-mm-diameter dishes coated with 2 ml of DMEM containing 10% fetal bovine serum (HyClone) and 0.6% agarose (Gibco-BRL). Cells were seeded on top of this layer at a density of 5 × 104 cells per plate in DMEM containing 10% fetal bovine serum and 0.3% agarose. Soft agar colony formation was evaluated 6 weeks after the initial plating. To determine growth to high density, cells were seeded at low density (5 × 104 per 60-mm-diameter dish) and fed every 3 days with DMEM containing 10% fetal bovine serum. Triplicate plates of cells were counted every 2 or 3 days.
Promoter reporter assays.
WT and
ARF
/
cell lines were plated at a density of
105 cells per 35-mm-diameter dish. Cells were transfected
the following day with Fugene 6 and 0.5 µg of the appropriate
luciferase reporter construct and pCMX-
-Gal (23). At
48 h after transfection, cells were washed twice in
phosphate-buffered saline and assayed for
-galactosidase and
luciferase activities as previously described (31).
| |
RESULTS |
|---|
|
|
|---|
Immortalization of MEFs by SV40 TAg.
It has been reported that
TAg-mediated transformation of WT MEFs requires the inactivation of the
pRB family by the LXCXE motif and J domain and inactivation of p53
function through the p53-binding domain (10, 76, 81). It is
possible that these transforming domains of TAg have other functions or
affect additional cellular targets. To determine whether these TAg
domains contributed to transformation in cells that had undergone
inactivation of the pRB and p53 pathways, we used selected knockout
mouse strains. INK4a
/
MEFs contain a
deletion of the second and third exons of the INK4a locus
(58). This prevents the expression of both
p16INK4a and p19ARF,
effectively disrupting both the p53 and the pRB pathways.
ARF
/
MEFs selectively delete the first exon
of the p19ARF protein and retain an intact
p16INK4a (37).
RB
/
MEFs lose pRB but express the
pRB-related proteins p107 and p130 (76).
/
, ARF
/
,
and RB
/
MEFs, we established cell lines that
express WT TAg or various mutants of TAg as depicted in Fig.
1. An intact HPD motif (residues 42 to
44) is essential for J domain function of TAg (38, 65, 68).
The H-to-Q point substitution (H42Q) in the HPD motif has been shown to
inactivate several J domain functions, including SV40 TAg-mediated
ori-dependent DNA replication (6). The LXCXE motif of TAg, contained within residues 103 to 107, binds to and inactivates pRB family members (13, 16, 20, 76). The K1 (E107K), C105G, and PVU-1 substitution mutations disrupt the ability of
TAg to bind to pRB, p107, and p130. The bipartite p53-binding domain of
TAg is located between residues 350 and 550 (40, 51). A
small in-frame deletion of residues 434 to 444 completely disrupts the
ability of TAg to bind p53 (40). The truncation mutants T1-350 and T1-135 lack the entire p53-binding region but retain an
intact J domain and LXCXE motif. All of the SV40 TAg cDNA constructs expressed similar levels of large TAg and did not express small t
antigen (68, 76; data not shown).
|
/
, INK4a
/
, and
RB
/
MEFs. Early-passage MEFs were
transfected to minimize the possibility that the cells had acquired
spontaneous mutations. Pools of transfectants were selected in
puromycin and tested for TAg expression. Expression of WT TAg or TAg
mutants was quite high in all pools of cells and varied less than
twofold (data not shown). WT and RB
/
MEFs
usually senesce within 10 to 20 passages, and any puromycin-resistant clone was likely to have undergone immortalization (76). In WT MEFs, we observed that only cells that expressed TAg constructs containing an intact p53-binding domain became immortalized, as had
been previously reported (40). An intact J domain or LXCXE motif was not required for immortalization. WT MEFs transfected with pEpuro only failed to produce any immortal lines. Similar results were observed with RB
/
MEFs,
although a few small colonies expressing either the
dl434-444 or T1-135 construct were observed (40,
71). Since the RB
/
MEFs expressing the
dl434-444 construct grew more slowly than cells transfected
with other TAg constructs, they were not used in transformation
studies. The T1-135 RB
/
MEFs grew slightly
faster and were tested in the soft agar assay.
Both ARF
/
and
INK4a
/
cells immortalized readily, as
determined by the generation of stable pools of puromycin-resistant
cells transfected by the puromycin resistance plasmid alone. This
observation is consistent with prior reports that
ARF
/
and INK4a
/
MEFs were either already immortalized or underwent immortalization very
readily (37, 58). Furthermore, the p53-binding domain of TAg
was not required for the immortalization of
INK4a
/
or ARF
/
MEFs. We were able to generate pools of cells that stably expressed WT
TAg or the J domain, LXCXE motif, or p53-binding domain mutants in the
ARF
/
and INK4a
/
MEFs. When these cells were examined by indirect immunofluorescence using a monoclonal antibody for TAg, more than 95% of the cells expressed detectable levels of TAg (data not shown). In contrast, when
we attempted to generate ARF
/
or
INK4a
/
MEFs expressing TAg with mutations in
both the pRB-binding and the p53-binding domains, only about 50% of
the cells expressed the TAg mutants (data not shown). We were unable to
generate populations of ARF
/
or
INK4a
/
MEFs that expressed in every cell the
K1-dl434-444 double mutation or T1-135 or T1-350 containing
a mutation in the LXCXE motif (T1-135K1 or T1-350K1). Similarly, a TAg
triple mutant in which the J domain, the LXCXE motif, and the
p53-binding domain were mutated (H42Q-K1-dl434-444) also did
not yield clones that expressed TAg in every cell. Although each of
these double- and triple-mutant transfectants formed as many colonies
as WT TAg transfectants, we found that less than half of the cells
lacked detectable TAg expression. Given the lack of uniform expression,
INK4a
/
or ARF
/
MEFs transfected with double- or triple-mutant TAg constructs were not
studied further.
Role of the LXCXE motif in anchorage-independent growth.
To
determine the ability of TAg or mutant derivatives to confer
anchorage-independent growth, the MEF cell lines were plated in soft
agar. Growth was evaluated visually, and colonies containing eight or
more cells were scored as transformants (Fig. 2A). WT TAg expression in
WT and RB
/
MEFs was capable of inducing
growth in soft agar in approximately 40 to 50% of cells seeded. In WT
and RB
/
MEFs, the J domain mutant H42Q
transformed almost as well as WT TAg, with nearly the same number and
size of colonies, indicating that the J domain was not required for
anchorage-independent growth (68). In contrast, TAgs
containing mutations in the LXCXE motif were unable to transform WT or
RB
/
MEFs (68, 76). Thus, an
intact LXCXE motif but not the J domain was necessary for the
transformation of WT and RB
/
MEFs. Similar
results were observed in p107
/
,
p130
/
, and
p107/p130
/
MEFs (Zalvide and DeCaprio,
unpublished). In each of these genetic backgrounds, the LXCXE mutants
failed to induce growth in soft agar, while both WT TAg and the J
domain mutant of TAg induced soft agar growth in more than 40% of the
cells seeded (data not shown). The truncated T1-135, lacking the
p53-binding domain, was able to induce soft agar growth of
RB
/
MEFs only slightly more efficiently than
the full-length LXCXE mutants, suggesting that the p53-binding domain
of TAg may contribute to anchorage-independent growth of
RB
/
MEFs.
/
MEFs disrupt the expression of
both p16INK4a and p19ARF,
these cells are expected to have at least partially inactivated the pRB
and p53 tumor suppressor pathways. We therefore reasoned that TAg might
not require the LXCXE motif or the p53-binding region to
transform INK4a
/
MEFs. As seen in Fig.
2A, WT TAg or mutants containing point substitutions in the LXCXE motif (K1, C105G, or PVU-1), a small in-frame deletion in the p53-binding domain (dl434-444), or
a deletion of the entire p53-binding domain (T1-135) were able to induce soft agar colony growth in INK4a
/
MEFs. Notably, some function of TAg was required for transformation of
INK4a
/
, as the pEpuro-only transfectants
were unable to grow in soft agar (Fig. 2A). Thus, expression of TAg
containing an intact LXCXE motif or an intact p53-binding region
conferred anchorage-independent growth in the
INK4a
/
cells.
|
/
MEFs that express
p16INK4a but not p19ARF
were transformed by the same TAg constructs that were able to transform INK4a
/
MEFs. TAg constructs containing
mutations in the J domain (H42Q), the LXCXE motif (K1, C105G, or PVU-1)
or the p53-binding domain (T1-135) were able to induce
ARF
/
MEFs to grow in soft agar with nearly
the same efficiency as WT TAg (Fig. 2A). Since
p19ARF was suspected to affect MDM2 and p53
function but not pRB function, the ability of the LXCXE mutants to form
soft agar colonies in ARF
/
MEFs was
unexpected. However, three different mutant constructs of the LXCXE
motif, each unable to bind pRB family members, were able to induce soft
agar colony growth as efficiently as WT TAg. Notably, the truncation
mutant T1-135, unable to bind to p53, also induced colony formation in
soft agar.
To confirm the ability of LXCXE TAg mutants to induce soft agar growth
in ARF
/
MEFs, we established a second series
of cells with additional TAg constructs. The level of TAg expression
was similar in each pool of ARF
/
MEFs, as
confirmed by Western blotting (Fig. 2C). Again, the three different
LXCXE mutant constructs were each capable of conferring the ability of
ARF
/
MEFs to grow in soft agar relative to
the pEpuro-only pools of transfectants (Fig. 2B). Furthermore, a J
domain-LXCXE double mutant, HQ-K1, was also capable of growth in soft
agar. This double mutant, though expected to have completely disrupted
any ability to perturb the pRB family of tumor suppressors, was nearly
as effective as the K1 and H42Q single mutants in inducing soft agar growth. In addition, three different p53-binding-defective mutants of
TAg, dl434-444, T1-350, and T1-135, were each able to
transform ARF
/
MEFs. Thus, in both
INK4a
/
and ARF
/
cells, mutants expressing either an intact p53-binding domain or LXCXE
motif were able to induce transformation, as measured by the ability to
induce anchorage-independent growth.
Growth to high density requires the J domain and the LXCXE
motif.
The TAg-transformed phenotype is also reflected in the
ability of adherent cells to grow to high density on plastic surfaces. TAg-transformed cells can grow to a higher density than nontransformed cells. To overcome a density arrest, cells must overcome signals for
growth arrest due to contact inhibition as well as growth factor
depletion. TAg induces high-density growth in cultured cells
(76). To determine the domains of TAg that participate in
inducing high-density growth, the growth rate of TAg-immortalized MEF
cell lines was determined. Cells were plated on a 10-cm-diameter plate
at a low density and refed with medium containing 10% serum every 3 days. At various intervals, three replica plates of each transformant
were harvested and counted. This growth experiment was repeated at
least twice, and the results of a typical experiment are shown in Fig.
3.
|
/
MEFs is entirely consistent with
previous reports (68).
WT TAg induced growth to very high density in
INK4a
/
MEFs, nearly twice as high as
observed in WT MEFs (Fig. 3B). In contrast, the J domain (H42Q) and
LXCXE (K1, C105G, and PVU-1) transformants grew to a density half of
that observed for MEFs expressing WT TAg but nearly twice that of the
pEpuro transformants. The p53-binding-defective mutant
dl434-444 grew to a slightly lower density than the J domain and LXCXE mutants but still resulted in significantly more cells than
the pEpuro-only MEFs. In contrast to the results observed in the
anchorage-independent growth assay, loss of the J domain, the LXCXE
motif, or the p53-binding domain impaired the ability of
INK4a
/
MEFs to grow to high density.
WT TAg induced ARF
/
MEFs to grow to
approximately twice the densities of MEFs transfected with the J domain
mutant, H42Q, and the LXCXE mutants, C105G and PVU-1 (Fig. 3C). The
LXCXE mutant K1 and the J domain-LXCXE double mutant HQ-K1 grew to a
slightly lesser extent than the other LXCXE mutants but still grew to a higher density than the pEpuro-only transfectants. Notably, the TAg
p53-binding domain mutants dl434-444 and T1-350 grew as well as WT TAg, suggesting that the p53-binding domain is not necessary for
growth to high density in ARF
/
MEFs.
Furthermore, ARF
/
MEFs that expressed T1-135
did not grow to as high a density as the full-length TAg, T1-350, or
dl434-444 constructs, suggesting that there may be an
additional transforming function within residues 135 to 350 of TAg.
Evidence for an additional transforming domain within these residues
has previously been proposed (15). The near-wild-type TAg
ability of the dl434-444 mutant to induce growth in
ARF
/
MEFs compared to
INK4a
/
MEFs may be accounted for by the
possibility that the INK4a
/
MEFs express an
N-terminal fragment of the p19ARF protein
encoded by the intact exon 1
in the INK4a locus
(53). The truncated p19ARF may be
able to inhibit MDM2 activity and thereby activate p53 (36).
Expression and activity of pRB in ARF
/
MEFs.
The soft agar experiments shown in Fig. 2A and B suggest
that while the LXCXE motif was required for TAg-dependent
anchorage-independent growth in WT and RB
/
MEFs, it was dispensable in INK4a
/
and
ARF
/
MEFs. This suggests that the loss of
p19ARF may have resulted in a partial
inactivation of the pRB growth suppression pathway in addition to the
p53 pathway. To explore this possibility, we examined the pRB and p53
pathways in WT and ARF
/
MEFs.
exon in the ARF
/
MEFs or the stable
expression of TAg may have affected expression of the nearby
p15INK4b or p16INK4a
genes. Loss of either p15INK4b or
p16INK4a could lead to an increase in cyclin
D-cdk4 activity, resulting in the hyperphosphorylation and inactivation
of the pRB family members. However, as shown in Fig.
4, p16INK4a was
expressed at relatively similar levels in WT and
ARF
/
MEFs established by various TAg
constructs, and only a slight variation of
p15INK4b expression was noted in the
ARF
/
MEFs. Thus, it is unlikely that the
loss of p16INK4a or
p15INK4b expression was responsible for the
ability of the LXCXE mutant in ARF
/
MEFs to
overcome the pRB growth suppression pathway in the soft agar assay.
Notably, the levels of p16INK4a and
p19ARF were low in the early-passage primary WT
MEFs and became significantly increased upon TAg-induced
immortalization. This increase in expression of
p19ARF has been reported during serial passage
of WT MEFs (37).
|
/
MEFs
affected expression of pRB family members. This was a distinct possibility given the observation that p19ARF
affects MDM2 function and MDM2 has been reported to bind to pRB (73). However, as shown in Fig.
5A, there was no significant difference
between TAg-expressing WT and ARF
/
MEFs in
the steady-state levels or phosphorylation state of pRB, p107, and
p130. As noted in the introduction, the LXCXE motif and J domain of TAg
cooperate to alter the phosphorylation state of p130 and p107 (68,
69). As can be seen in Fig. 5A, the hyperphosphorylated forms of
p130 and p107 were not present in the WT or
ARF
/
MEFs expressing WT TAg (lanes 2 and 9),
dl434-444 (lane 15), T1-350 (lane 16), and T1-135 (lane 17).
In contrast, the hyperphosphorylated forms of p107 and p130 were
present in WT and ARF
/
MEFs established by
the J domain mutant H42Q (lanes 3 and 10), the LXCXE mutant constructs
K1 (lanes 4 and 11), C105G (lanes 5 and 12), and PVU-1 (lanes 6 and
13), and the double mutant HQ-K1 (lanes 7 and 14). Thus, the pRB family
of proteins were expressed and normally phosphorylated in the presence
of LXCXE and J domain mutants of TAg in a manner indistinguishable
between WT and ARF
/
MEFs.
|
/
MEFs that expressed TAg or an LXCXE mutant, we examined the activity of
an E2F promoter reporter containing three consensus E2F sites (43). As shown in Fig. 6A, WT
TAg or the J domain mutant H42Q could transactivate the 3xE2F-Luc
reporter relative to non-TAg-expressing WT or
ARF
/
MEFs. Similarly, the p53-binding mutant
T1-135 could also transactivate the 3xE2F-Luc reporter in
ARF
/
MEFs. In contrast, the activity of the
E2F promoter reporter was significantly lower in MEFs established by
LXCXE mutants of TAg. The LXCXE mutant K1 was unable to transactivate
the 3xE2F-Luc reporter relative to controls in either WT or
ARF
/
MEFs. A promoter reporter containing
three mutated E2F sites was not affected by expression of TAg or any of
the mutated TAg constructs (data not shown). We conclude that the
ability of the pRB family to decrease transcription through the E2F
site was not abrogated in the LXCXE mutant-expressing
ARF
/
MEFs.
|
Expression and activity of p53 in ARF
/
MEFs.
SV40 TAg has a well-described ability to bind to p53 and to
increase its level of expression at least in part through decreasing the turnover rate (70). As shown in Fig. 5B (top panel), p53 expression was extremely low in the pEpuro
ARF
/
MEFs (lane 8) as well as in
early-passage cultures of WT MEFs (lane 1). In contrast, WT and
ARF
/
MEFs expressing WT TAg (lanes 2 and 9),
LXCXE mutants (lanes 4 to 6 and 11 to 13), or J domain mutants (lanes
3, 7, 10, and 14), which are capable of binding to p53, had
significantly increased levels of p53. This observation suggests that
TAg could stabilize p53 both in WT cells and in cells that have lost
p19ARF. In contrast, the expression of
p53-binding mutants dl434-444 (lane 15), T1-350 (lane 16),
and T1-135 (lane 17) did not result in increased steady-state levels of p53.
/
MEFs, we measured the
activity of two p53-responsive promoter reporters, cyclin G and p21, in
WT and ARF
/
MEFs. As shown in Fig. 6B, WT
TAg and C105G, an LXCXE mutant, strongly repressed the transcription of
the cyclin G promoter relative to the activity observed in the
pEpuro-transfected ARF
/
MEFs. In contrast,
p53-binding mutants of TAg, dl434-444 and T1-350, failed to
repress the activity of the cyclin G promoter. Similar results were
observed with the p21CIP promoter. WT TAg, the J
domain mutant H42Q, and two different LXCXE mutants repressed the
activity of the p21CIP promoter, while the
p53-binding mutant dl434-444 was unable to repress this
promoter. The levels of p21CIP protein seen in
TAg-expressing WT and ARF
/
MEFs reflected
the changes seen in promoter activity (Fig. 5B, lower panel).
p21CIP levels were high in WT MEFs and in the
ARF
/
pEpuro-only transfectants (lanes 1 and
8). p21CIP levels were also quite high in the
ARF
/
cell lines expressing any of the
p53-binding mutants of TAg, dl434-444 (lane 15), T1-135
(lane 16), or T1-350 (lane 17). These results suggest that in
ARF
/
MEFs stably expressing p53-binding
mutants of TAg, p53 retained the ability to act as a DNA-specific
transcription factor.
| |
DISCUSSION |
|---|
|
|
|---|
In this report, the contribution of the J domain, LXCXE motif, and
p53-binding domain of TAg to transformation of WT,
RB
/
, INK4a
/
, and
ARF
/
MEFs was examined. The goal was to
determine whether the loss or functional inactivation of certain tumor
suppressor genes would reduce the requirement for these domains in TAg
transformation. WT SV40 TAg was able to induce growth of MEFs derived
from each of these genetic backgrounds to high density and in an
anchorage-independent manner. In WT and RB
/
MEFs, TAg's p53-binding domain was required for efficient
immortalization, the LXCXE motif was needed for anchorage-independent
and high-density growth, and the J domain was required for high-density
growth. In contrast, TAg had different requirements for transformation of MEFs that did not express p16INK4a or
p19ARF. The p53-binding domain of TAg was not
required for immortalization, high-density growth, or soft agar growth
of INK4a
/
or ARF
/
MEFs. These results were not unexpected given that the loss of p19ARF expression has been shown to perturb the
p53 growth suppression pathway, thereby reducing the requirement for
p53 inactivation by TAg binding. The LXCXE motif and J domain were
required for high-density growth of INK4a
/
MEFs, suggesting that the pRB family was functionally intact despite
the loss of p16INK4a expression. The most
unexpected observation was that the LXCXE motif was not required for
anchorage-independent growth of either INK4a
/
or ARF
/
MEFs. This latter result would seem to suggest that the growth suppression functions of the pRB family were disrupted in
ARF
/
and INK4a
/
MEFs during anchorage-independent growth. Notably, the
ARF
/
MEFs which expressed
p16INK4a but not p19ARF
behaved similarly as INK4a
/
MEFs in response
to TAg. Both cell types were induced to grow in soft agar when
expressing either p53-binding domain or LXCXE motif mutants of TAg.
Since p19ARF was reported to regulate the p53
pathway but not the pRB pathway, the LXCXE mutants were not expected to
induce anchorage-independent growth in ARF
/
MEFs that expressed p16INK4a.
It is unlikely that INK4a
/
and
ARF
/
MEFs expressing the LXCXE mutant TAg
constructs have acquired additional specific genetic modifications that
enabled them to grow in soft agar. All assays were performed with pools
of transfected cells to reduce the possibility of clonal variation.
Furthermore, similar transformation results were obtained with several
independently performed transfections. INK4a
/
or ARF
/
MEFs could be readily immortalized in the absence of TAg, as evidenced
by the efficient ability to select for colonies in the presence of the
puromycin resistance gene alone. However,
INK4a
/
or ARF
/
MEFs expressing the puromycin resistance gene alone were not transformed, as determined by their inability to grow in soft agar or
to high density. Expression of TAg conferred an additional transforming
activity that permitted growth under these more stringent conditions.
These observations are consistent with the demonstration that
expression of activated H-ras induced transformation of
ARF
/
and INK4a
/
MEFs (37, 58).
Growth in soft agar measures the ability of fibroblasts to acquire
anchorage-independent growth. Anchorage-independent growth has been
considered a stringent in vitro method for predicting the tumor
formation potential of TAg-transformed fibroblasts (55). However, it has been reported that the ability of TAg-transformed cells
to form tumors in nude mice does not require an intact LXCXE motif
(71). To date, there has been an absolute requirement for an
intact LXCXE motif in anchorage-independent growth of TAg-transformed WT MEFs in soft agar (10, 11, 71, 76). Here, we
observed that the LXCXE motif was not required for soft agar
growth of INK4a
/
and
ARF
/
MEFs.
Notably, expression of HQ-K1, a TAg containing inactivating mutations
in both the LXCXE motif and J domain, induced
INK4a
/
or ARF
/
MEFs to grow in soft agar. Despite loss of the J domain and LXCXE motif, HQ-K1 could bind to and stabilize p53. Transformation by this
and other LXCXE mutants would seem to indicate that binding to p53
conferred a growth advantage and that p53 function was not completely
eliminated by the loss of p19ARF. Consistent
with this possibility, p53 appeared to be functional in the
ARF
/
MEFs that express TAg with mutations in
the p53-binding domain, as demonstrated by the increased activity of
the p21CIP and cyclin G promoters (Fig. 6B) as
well as by the increased expression of p21CIP
(Fig. 5B). This potential for activation of p53 in
ARF
/
MEFs did not seem to pose a barrier to
immortalization or to the ability of the p53-binding mutant TAgs to
induce growth in soft agar or to high density.
The ability of adherent cells to grow to high density may reflect the
cell's response to limiting amounts of growth factors and nutrients as
the cell number increases. An intact J domain and LXCXE motif were both
required for TAg to induce growth to high density in WT,
RB
/
, ARF
/
, and
INK4a
/
MEFs (Fig. 3 and reference
68). The contribution of the J domain to
high-density growth of these MEFs is consistent with previous work that
suggests that the J domain cooperates with the LXCXE motif to
inactivate pRB, p107, and p130 (27, 60, 68). Further evidence for the J domain activity includes the reduction in
phosphorylation of p107 and p130 in WT and
ARF
/
MEFs expressing TAg (Fig. 5B). We have
previously reported that J domain mutant constructs were as effective
as WT TAg in promoting the high-density growth of p130
/
p107
/
double-knockout MEFs, suggesting that the J
domain specifically contributed to the functional inactivation of p107
and p130 (68). The observation that the J domain and the
LXCXE motif were required for overcoming density arrest of
INK4a
/
and ARF
/
MEFs suggests that the pRB family including p107 and p130 was functionally intact in adherent INK4a
/
and
ARF
/
MEFs. Therefore, loss of
p16INK4a or p19ARF
expression did not perturb the pRB growth suppression activity in the
density arrest assay. It will be interesting to determine whether TAgs
containing J domain or LXCXE motif mutants will have the ability to
induce high-density or soft agar growth in MEFs homozygously deficient
in Rb, p107, and p130.
The J domain cooperates with the LXCXE motif to inactivate pRB function
in a variety of assays including dissociation of pRB-E2F complexes and
overriding pRB repression of E2F-dependent promoters (68,
77). Recent reports suggest that the LXCXE motif of SV40 and
polyomavirus large T antigens may also inhibit certain pRB functions
independently of the J domain. For example, WT TAg and a J domain
mutant (H42Q) but not an LXCXE mutant (K1) could override a p53-induced
growth arrest (25). The LXCXE motif but not the J domain was
required for polyomavirus large T antigen-induced apoptosis of C2C12
myoblasts upon serum withdrawal (61). In this report, we
observed that an intact LXCXE motif but not the J domain was required
for activation of the 3xE2F promoter reporter in WT and
ARF
/
MEFs (Fig. 6A). In addition, an intact
J domain was not required for inducing soft agar growth of MEFs derived
from any of the genetic backgrounds studied. These distinctions may
reflect the ability of TAg to perturb different growth-suppressing
functions of the pRB family. Alternatively, the LXCXE motif may target
other cellular proteins that do not require the contribution of the J domain.
As mentioned earlier, the most unexpected observation was that the
LXCXE mutants of TAg could induce anchorage-independent growth of
ARF
/
MEFs. There are several models to
explain how the LXCXE mutant TAgs were able to confer
anchorage-independent growth of the ARF
/
and
INK4a
/
MEFs. One possibility is that
p19ARF is involved in the regulation of both p53
and pRB and that loss of p19ARF led to at least
partial deregulation of both pathways. If this were true, it could
explain why ARF
/
mice display the same tumor
types as INK4a
/
mice. Several reports
suggest that p19ARF may regulate pRB function.
For example, the expression of an antisense construct to
p19ARF could overcome a growth arrest induced by
p16INK4a whereas the expression of an antisense
construct to p16INK4a was unable to overcome a
growth arrest induced by p19ARF, suggesting that
p19ARF has functions that overlap with those of
p16INK4a (8). In addition,
overexpression of p19ARF was able to induce a
growth arrest in p53
/
cells but not in
p53
/
cells that overexpressed E2F-1, again
suggesting that p19ARF may be able to suppress
growth through regulation of pRB as well as p53 (8). In
addition, MDM2 may be directly involved in the regulation of pRB by
binding to the C-terminal region of pRB (73). Alternatively,
MDM2 may promote the rapid degradation of E2F-1 in cells that lack
p19ARF (4). Under such conditions, it
is likely that pRB would be at least partially unable to act as a tumor
suppressor gene, since pRB binding to E2F-1 is required for
transcriptional repression of E2F-dependent promoters and tumor
suppression (22, 75). However, our data do not support such
a scenario since we were unable to detect any differences in E2F
activity between WT and ARF
/
MEFs
transformed by LXCXE mutants of TAg. Furthermore, the steady-state levels of E2F-1 appeared similar between the WT and
ARF
/
cells as determined by Western blotting
(data not shown). We have not extensively tested the ability of the pRB
family to bind and inactivate other members of the E2F family in the
TAg-transformed MEFs. It is possible that the activities of one or more
members of the E2F family are diminished in
ARF
/
MEFs. Alternatively, it is possible
that the LXCXE region of TAg targets an additional growth or
tumor-suppressing protein whose activity may be lacking or diminished
in ARF
/
MEFs.
The ability of the LXCXE mutant constructs to induce
anchorage-independent growth in ARF
/
MEFs
may also reflect a novel transforming function of TAg. This additional
activity could overcome the growth inhibition induced by the pRB
family. p300 is an especially interesting candidate for this additional
activity. p300 was originally cloned as an adenovirus E1A-associated
protein (18), and both p300 and the highly related
CREB-binding protein (CBP) can be functionally inactivated by E1A
(1, 49). E1A binds directly to p300 and CBP through a domain
distinct from its pRB family-binding motif. E1A can stimulate entry
into the cell cycle from quiescence using either the p300/CBP-binding
region or the pRB-binding LXCXE motif (66, 78). Thus, E1A
binding to p300/CBP can circumvent at least some of the
growth-inhibitory functions of pRB. The mechanism of the E1A/p300
growth-promoting activity, however, is not completely understood. The
effect of p300 binding to TAg also remains unknown; however, it is
possible that this permits TAg to overcome the growth-suppressing
function of the pRB family in ARF
/
MEFs
(2, 45). The p53-binding domain of TAg can also bind to MDM2
(29). Thus, TAg could perturb the function of several growth-regulatory factors, including p53, MDM2, p300/CBP, and pRB.
In addition to the three TAg domains described here, it is possible
that TAg has additional domains that contribute to transformation. The
N terminus of TAg is known to bind to other cellular proteins in
addition to the pRB family, most notably a 185-kDa protein that is as
yet uncharacterized (42). In addition, there has been some
suggestion that the DNA-binding domain of TAg (residues 131 to 280) may
contribute to growth promotion and transformation. The DNA-binding
region is involved in transcriptional transactivation of many cellular
and viral promoters that may promote cellular growth. For example, a
point substitution mutation in the DNA-binding domain reduced the
ability of TAg to induce DNA synthesis in quiescent cells (15,
34). In our experiments, ARF
/
MEFs
expressing T1-135 grew to half the density of those expressing full-length TAg, T1-350, or dl434-444 (Fig. 3). This may
indicate that the DNA-binding region (residues 131 to 280) or perhaps
the zinc finger (residues 302 to 320) can contribute to TAg-mediated transformation, though the nature and extent of this transforming activity are as yet uncharacterized.
In conclusion, these experiments have demonstrated that mutations in
either the p53-binding domain or the LXCXE motif did not diminish the
ability of TAg to confer anchorage-independent growth of
INK4a
/
and ARF
/
MEFs. These results support the notion that the N-terminal and C-terminal regions of TAg have transforming functions beyond the disruption of the pRB and p53 tumor suppressor pathways. Furthermore, these results suggest that p19ARF may have tumor
suppression functions in addition to control of the p53 tumor
suppressor gene.
| |
ACKNOWLEDGMENTS |
|---|
We are grateful to Sorab Dalal and Hilde Stubdal for critical
reading of the manuscript. We thank members of the DeCaprio laboratory
for advice and support. We gratefully acknowledge the gift of
ARF
/
MEFs and p19ARF
antiserum from Martine F. Roussel (St. Jude Children's Hospital), INK4a
/
MEFs from Ronald A. DePinho
(Dana-Farber Cancer Institute), the cyclin G promoter reporter plasmid
pGL3-cyclin G-Luc from Carol Prives (Columbia University), pWWP-luc
from Bert Vogelstein (The Johns Hopkins University School of Medicine),
and dl434-444 from M. Judy Tevethia (Pennsylvania State
University College of Medicine).
H.A.H.C. was supported by a fellowship from the Deutsche Forschungsgemeinschaft. A.M.B. was supported by NIH training grant 2T32CA09361 and NRSA fellowship F32CA81745. J.A.D. is a Scholar of the Leukemia and Lymphoma Society. This work was supported in part by Public Health Service grant RO1-CA63113.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Dana-Farber Cancer Institute, Mayer 457, 44 Binney St., Boston, MA 02115. Phone: (617) 632-3825. Fax: (617) 632-4760. E-mail: james_decaprio{at}dfci.harvard.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Arany, Z., D. Newsome, E. Olread, D. M. Livingston, and R. Eckner. 1995. A family of transcriptional adaptor proteins targeted by the E1A oncoprotein. Nature 374:81-84[CrossRef][Medline]. |
| 2. | Avantaggiati, M. L., M. Carbone, A. Graessmann, Y. Nakatani, B. Howard, and A. S. Levine. 1996. The SV40 large T antigen and adenovirus E1a oncoproteins interact with distinct isoforms of the transcriptional co-activator, p300. EMBO J. 15:2236-2248[Medline]. |
| 3. |
Bargonetti, J.,
I. Reynisdottir,
P. N. Friedman, and C. Prives.
1992.
Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53.
Genes Dev.
6:1886-1898 |
| 4. |
Blattner, C.,
A. Sparks, and D. Lane.
1999.
Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53.
Mol. Cell. Biol.
19:3704-3713 |
| 5. | Calabro, V., T. Parisi, A. Di Cristofano, and G. La Mantia. 1999. Suppression of Ras-mediated NIH3T3 transformation by p19ARF does not involve alterations of cell growth properties. Oncogene 18:2157-2162[CrossRef][Medline]. |
| 6. |
Campbell, K. S.,
K. P. Mullane,
I. A. Ibraham,
H. Stubdal,
J. Zalvide,
J. M. Pipas,
P. A. Silver,
T. M. Roberts,
B. S. Schauffhausen, and J. A. DeCaprio.
1997.
DnaJ/hsp40 chaperone domain of SV40 large T antigen promotes efficient viral DNA replication.
Genes Dev.
11:1098-1110 |
| 7. | Cao, L., B. Faha, M. Dembski, L.-H. Tsai, E. Harlow, and N. Dyson. 1992. Independent binding of the retinoblastoma protein and p107 to the transcription factor E2F. Nature 355:176-179[CrossRef][Medline]. |
| 8. | Carnero, A., J. D. Hudson, C. M. Price, and D. H. Beach. 2000. p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nat. Cell Biol. 2:148-155[CrossRef][Medline]. |
| 9. | Chellappan, S. P., S. Hiebert, M. Mudryj, J. M. Horowitz, and J. R. Nevins. 1991. The E2F transcription factor is a cellular target for the RB protein. Cell 65:1053-1061[CrossRef][Medline]. |
| 10. |
Chen, S., and E. Paucha.
1990.
Identification of a region of simian virus 40 large T antigen required for cell transformation.
J. Virol.
64:3350-3357 |
| 11. | Christensen, J. B., and M. J. Imperiale. 1995. Inactivation of the retinoblastoma susceptibility protein is not sufficient for the transforming function of the conserved region 2-like domain of simian virus 40 large T antigen. J. Virol. 69:3945-3948[Abstract]. |
| 12. | Conzen, S. D., and C. N. Cole. 1995. The three transforming regions of SV40 T antigen are required for immortalization of primary mouse embryo fibroblasts. Oncogene 11:2295-2302[Medline]. |
| 13. |